Alnylam 制药

最新新闻

• Cantor Fitzgerald Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Cuts Target Price to $325
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  Bernstein Initiates Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Announces Target Price $376
  \u5e02\u573a\u8d44\u8baf · 2026/8/24
• 评级变动
  Needham Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $357
  \u5e02\u573a\u8d44\u8baf · 2026/9/18
• 评级变动
  Barclays Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $450
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• 评级变动
  CCORF Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $429
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• 评级变动
  Morgan Stanley Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Maintains Target Price $300
  \u5e02\u573a\u8d44\u8baf · 2026/9/13
• 评级变动
  Bernstein Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $376
  \u5e02\u573a\u8d44\u8baf · 2026/9/26
• 评级变动
  Truist Financial Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/18
• 评级变动
  Citi Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Cuts Target Price to $340
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• 评级变动
  Stifel Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $318
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $315 to $455
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Cuts Target Price to $345
  \u5e02\u573a\u8d44\u8baf · 2026/10/8
• 评级变动
  J.P. Morgan Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $375
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  BMO Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $318
  \u5e02\u573a\u8d44\u8baf · 2026/9/18
• 评级变动
  Evercore Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Cuts Target Price to $325
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• BofA Securities Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• J.P. Morgan Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Cuts Target Price to $369
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), AxoGen (AXGN) and Biohaven Ltd. (BHVN)
  TipRanks · 2026/9/30
• 评级变动
  A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $318 to $489
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• 评级变动
  H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $455
  \u5e02\u573a\u8d44\u8baf · 2026/9/21
• 评级变动
  A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $230 to $420
  \u5e02\u573a\u8d44\u8baf · 2026/8/1
• 评级变动
  Barclays Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Cuts Target Price to $450
  \u5e02\u573a\u8d44\u8baf · 2026/8/3

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。